Health Canada Approves Roche’s Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy
DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed…